Get the Stockscreener App
41.55
2.01%
0.82
After Hours:
42.05
0.50
+1.20%
Kymera Therapeutics Inc stock is traded at $41.55, with a volume of 814.24K.
It is up +2.01% in the last 24 hours and down -7.46% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$40.73
Open:
$40.18
24h Volume:
814.24K
Relative Volume:
0.96
Market Cap:
$2.71B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-13.40
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+1.71%
1M Performance:
-7.46%
6M Performance:
+12.66%
1Y Performance:
-2.30%
1-Day Range:
$40.01
$41.84
1-Week Range:
$36.65
$41.84
52-Week Range:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
41.55 | 2.91B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript - Insider Monkey
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Extends Cash Runway, Boosts Funding through Immunology Pipeline Advancements and Collaborations. - AInvest
Kymera Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Kymera Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Earnings call transcript: Kymera Therapeutics Q2 2025 results miss forecasts By Investing.com - Investing.com South Africa
Kymera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline By Investing.com - Investing.com Australia
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Revenue Drops 55 Percent in Q2 - The Globe and Mail
Kymera’s Losses Widen But Wall Street Stays Optimistic - Finimize
Kymera Therapeutics, Inc. SEC 10-Q Report - TradingView
Kymera Therapeutics' Q2 2025 Earnings Miss: A Test of Resilience in the TPD Space? - AInvest
Kymera Therapeutics Q2 Loss Widens, Collaboration Revenue Falls - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Revenue $11.5M, vs. FactSet Est of $22.2M - MarketScreener
Earnings Flash (KYMR) Kymera Posts Q2 Loss $0.95 a Share, vs. FactSet Est of $0.89 Loss - MarketScreener
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Q2 revenue misses expectations, net loss widens - TradingView
Kymera Reports Phase 1 Success, Secures $750M Gilead Partnership with $1B Cash Position | KYMR Stock News - Stock Titan
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Earnings Preview: What to Expect - AInvest
Kymera Therapeutics KYMR Q2 2025 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance
Kymera Therapeutics Becomes Oversold (KYMR) - Nasdaq
Earnings Preview: KYMR to Report Financial Results Pre-market on August 11 - 富途牛牛
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times
Kymera Therapeutics reports Q2 2025 results, plans call on August 11. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan
Is Kymera Therapeutics Inc. a growth stock or a value stockFree Investment Community - Jammu Links News
How does Kymera Therapeutics Inc. generate profit in a changing economyTransform your portfolio with high-yield stocks - Jammu Links News
What catalysts could drive Kymera Therapeutics Inc. stock higher in 2025Get expert analysis on top stock picks - Jammu Links News
What makes Kymera Therapeutics Inc. stock price move sharplyAchieve consistent profits with proven methods - Jammu Links News
Should I hold or sell Kymera Therapeutics Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
How many analysts rate Kymera Therapeutics Inc. as a “Buy”Stay ahead with daily market updates - Jammu Links News
Why is Kymera Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What is Kymera Therapeutics Inc. company’s growth strategyExplosive earning power - Jammu Links News
What analysts say about Kymera Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
How strong is Kymera Therapeutics Inc. company’s balance sheetSwing Trade Review With Proven Results - Jammu Links News
Kymera Therapeutics: A Biotech Company with a Promising Future - AInvest
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):